PROMIS NEUROSCIENCES TO PRESENT DATA AT 2019 ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE

TORONTO, Ontario and CAMBRIDGE, Mass. —July 10, 2019 — ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, will give an oral presentation on its lead clinical candidate, PMN310 for Alzheimer’s disease, at the annual Alzheimer’s Association International Conference® (AAIC), which occurs July 14-18.  A second poster presentation focuses on the behavior of misfolded TDP43 involved in the development of neurological disorders such as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia. MORE>>